Honkamp Krueger Financial Services Inc. trimmed its holdings in shares of Allergan plc (NYSE:AGN) by 8.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,425 shares of the company’s stock after selling 431 shares during the period. Honkamp Krueger Financial Services Inc.’s holdings in Allergan were worth $724,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Peloton Wealth Strategists lifted its holdings in shares of Allergan by 37.1% during the 3rd quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock valued at $2,149,000 after buying an additional 2,835 shares during the period. Sumitomo Life Insurance Co. lifted its holdings in shares of Allergan by 39.0% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock valued at $3,099,000 after buying an additional 4,244 shares during the period. Clear Harbor Asset Management LLC lifted its holdings in shares of Allergan by 67.7% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 5,039 shares of the company’s stock valued at $1,033,000 after buying an additional 2,035 shares during the period. Alta Capital Management LLC lifted its holdings in shares of Allergan by 1.4% during the 3rd quarter. Alta Capital Management LLC now owns 161,377 shares of the company’s stock valued at $33,074,000 after buying an additional 2,151 shares during the period. Finally, Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Allergan by 16.1% during the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 5,177 shares of the company’s stock valued at $1,061,000 after buying an additional 718 shares during the period. Institutional investors and hedge funds own 79.66% of the company’s stock.
Shares of Allergan plc (NYSE AGN) opened at $164.04 on Tuesday. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $54,185.75, a PE ratio of -12.22, a price-to-earnings-growth ratio of 1.16 and a beta of 1.19. Allergan plc has a twelve month low of $156.00 and a twelve month high of $256.80.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, beating the Zacks’ consensus estimate of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm earned $3.90 earnings per share. equities research analysts predict that Allergan plc will post 15.57 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a yield of 1.76%. Allergan’s dividend payout ratio (DPR) is currently -20.86%.
Several equities analysts have recently weighed in on AGN shares. Zacks Investment Research raised Allergan from a “sell” rating to a “hold” rating in a report on Monday, October 23rd. Royal Bank of Canada set a $250.00 price target on Allergan and gave the company a “buy” rating in a report on Sunday, October 29th. They noted that the move was a valuation call. Cantor Fitzgerald set a $231.00 price target on Allergan and gave the company a “hold” rating in a report on Wednesday, November 1st. Wells Fargo & Co reissued an “outperform” rating and set a $245.00 price target (down from $258.00) on shares of Allergan in a report on Thursday, November 2nd. Finally, Morgan Stanley decreased their target price on Allergan from $228.00 to $200.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $227.23.
In other Allergan news, Director Chris W. Bodine purchased 3,030 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, with a total value of $499,253.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Allergan plc (AGN) Holdings Reduced by Honkamp Krueger Financial Services Inc.” was reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/02/20/allergan-plc-agn-holdings-reduced-by-honkamp-krueger-financial-services-inc.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.